Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection.
Groups of mice infected intravenously with Candida albicans were treated intraperitoneally with amphotericin B, caspofungin, or fluconazole, starting at intervals before and after challenge. Survival was longest and tissue burdens were most reduced with early treatment, and survival times fell proportionately as treatment was delayed, reinforcing clinical recommendations for the earliest possible initiation of antifungal therapy.
MacCallum
Donna M
DM
Aberdeen Fungal Group, School of Medical Sciences, Institute of Medical Sciences, Aberdeen, United Kingdom.
Odds
Frank C
FC
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001921:Brain / Q000382:microbiology; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D000077336:Caspofungin; D003114:Colony-Forming Units Assay; D054714:Echinocandins; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D055666:Lipopeptides; D051379:Mice; D008807:Mice, Inbred BALB C; D010456:Peptides, Cyclic / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; D015725:Fluconazole; D000077336:Caspofungin